Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CAmutant, hormone receptor-positive breast cancer

Category Primary study
JournalJournal of Clinical Oncology
Year 2022
This article has no abstract
Epistemonikos ID: b9a0515bb2a84cc45906ba03a5b0ee2c86628876
First added on: Feb 15, 2025